BioInvent and Cambridge Antibody Technology sign Licensing Agreement
Advertisement
BioInvent International AB announced that it has entered into a licence agreement with Cambridge Antibody Technology. Under the agreement BioInvent and its partners receive rights to use CAT's antibody phage display patent estate to develop products from BioInvent's n-CoDeR antibody libraries. As part of the agreement BioInvent has agreed to withdraw its opposition to CAT's patents filed at the European Patent Office in Munich. This agreement together with previous acquired licences gives BioInvent freedom to use all relevant parts of phage display to develop products from n-CoDeR.
CAT will receive an initial licence fee from BioInvent and future payments depending on how many therapeutic antibodies BioInvent and its partners develop using CAT's patented technology. If therapeutic or diagnostic products are successfully developed CAT will receive milestone payments and royalties on sales of such products.
With this and previously acquired licences BioInvent has rights to all relevant phage display and antibody format patents in drug development for its business. These include licences from Biosite Diagnostics (US), CAT (UK), Dyax (US), Enzon (US), Micromet (Germany) and XOMA (US). Under certain of these licences BioInvent will pay royalties following successful product development.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous